Vaccines 2013, 1(1), 1-16; doi:10.3390/vaccines1010001
Review

Peptide Vaccine Therapy in Colorectal Cancer

email, email and * email
Received: 6 July 2012; in revised form: 15 August 2012 / Accepted: 16 August 2012 / Published: 24 August 2012
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract: Colorectal cancer is the third most common cause of cancer-related deaths and the second most prevalent (after breast cancer) in the western world. High metastatic relapse rates and severe side effects associated with the adjuvant treatment have urged oncologists and clinicians to find a novel, less toxic therapeutic strategy. Considering the limited success of the past clinical trials involving peptide vaccine therapy to treat colorectal cancer, it is necessary to revise our knowledge of the immune system and its potential use in tackling cancer. This review presents the efforts of the scientific community in the development of peptide vaccine therapy for colorectal cancer. We review recent clinical trials and the strategies for immunologic monitoring of responses to peptide vaccine therapy. We also discuss the mechanisms underlying the therapy and potential molecular targets in colon cancer.
Keywords: peptide vaccine therapy; colorectal cancer; EphA2; survivin; SART3; CEA and MUC-1
PDF Full-text Download PDF Full-Text [327 KB, Updated Version, uploaded 18 September 2012 16:34 CEST]
The original version is still available [287 KB, uploaded 27 August 2012 16:39 CEST]

Export to BibTeX |
EndNote


MDPI and ACS Style

Bartnik, A.; Nirmal, A.J.; Yang, S.-Y. Peptide Vaccine Therapy in Colorectal Cancer. Vaccines 2013, 1, 1-16.

AMA Style

Bartnik A, Nirmal AJ, Yang S-Y. Peptide Vaccine Therapy in Colorectal Cancer. Vaccines. 2013; 1(1):1-16.

Chicago/Turabian Style

Bartnik, Aleksandra; Nirmal, Ajit Johnson; Yang, Shi-Yu. 2013. "Peptide Vaccine Therapy in Colorectal Cancer." Vaccines 1, no. 1: 1-16.

Vaccines EISSN 2076-393X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert